GSK vs VRTX: stock comparison and AI forecast
Gsk Plc (GSK) and Vertex Pharmaceuticals Inc / Ma (VRTX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
GSK Gsk Plc
- Market Cap
- $101.54B
- P/E Ratio
- 5.6x
- Size
- large-cap
- AI Forecast
VRTX Vertex Pharmaceuticals Inc / Ma
- Market Cap
- $137.50B
- P/E Ratio
- 34.9x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- VRTX is 1.4 times larger than GSK by market capitalization ($137.50B against $101.54B).
- GSK trades at 5.5 times trailing earnings, VRTX at 34.9 times.
- GSK carries 2.76 times debt per unit of equity, against 0.57 times for VRTX.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | GSK | VRTX |
|---|---|---|
| Market Cap | $101.54B | $137.50B |
| P/E Ratio | 5.55x | 34.93x |
| P/B Ratio | – | 6.58x |
| EPS | $9.08 | $15.53 |
| Book Value/Share | – | $82.49 |
| Revenue/Share | $81.00 | $51.10 |
| FCF/Share | $15.23 | $12.63 |
Profitability & Margins
| Metric | GSK | VRTX |
|---|---|---|
| ROE | – | 19.0% |
| ROA | – | 12.2% |
| ROIC | – | 15.5% |
| Gross Margin | 70.8% | 85.5% |
| Operating Margin | 20.3% | 33.2% |
| Net Margin | – | 30.7% |
| EBT Margin | 18.2% | 36.8% |
| Tax Rate | 13.7% | 16.5% |
Financial Health
| Metric | GSK | VRTX |
|---|---|---|
| Current Ratio | 0.82x | 2.34x |
| Quick Ratio | 0.54x | 1.89x |
| D/E Ratio | 2.76x | 0.57x |
| Financial Leverage | – | 1.57x |
| Interest Coverage | – | 245.8x |
| Working Capital | -$5.23B | $6.69B |
Cash Flow
| Metric | GSK | VRTX |
|---|---|---|
| Operating Cash Flow | $37.61B | $3.69B |
| Free Cash Flow | $30.73B | $3.20B |
| Capital Spending | -$6.88B | -$492M |
| OCF Growth YoY | -13.3% | -0.6% |
| FCF Growth YoY | 0.0% | -4.0% |
| FCF/Sales | 18.8% | 24.7% |
| CapEx/Sales | 4.2% | 3.8% |
Operational Efficiency
| Metric | GSK | VRTX |
|---|---|---|
| Asset Turnover | – | 0.40x |
| Receivables Turnover | 16.6x | 5.6x |
| Inventory Turnover | 6.1x | 0.8x |
| Fixed Assets Turnover | 13.3x | 7.6x |
| Days Sales Outstanding | 22 days | 65 days |
| Days Inventory | 60 days | 437 days |
| Payables Period | 155 days | 92 days |
| Cash Conversion Cycle | -73 days | 410 days |
Income Statement
| Metric | GSK | VRTX |
|---|---|---|
| Total Revenue | $163.43B | $12.95B |
| Operating Income | $33.20B | $4.30B |
| Net Income | – | $3.98B |
| R&D Expense | $33.87B | $4.25B |
| SG&A Expense | $50.02B | $2.41B |
| Cost of Goods Sold | $47.81B | $1.87B |
Dividend & Shareholder Information
| Metric | GSK | VRTX |
|---|---|---|
| Shares Outstanding | 2017M | 253M |
| Net Income Growth | – | 8.2% |
| EPS Growth | 87.6% | 8.6% |
GSK vs VRTX: stock comparison and AI forecast
Which is bigger, GSK or VRTX?
VRTX is 1.4 times larger than GSK by market capitalization ($137.50B against $101.54B).
Which is cheaper on earnings, GSK or VRTX?
GSK trades at 5.5 times trailing earnings, VRTX at 34.9 times.
Which one does Intratio's AI model rank higher, GSK or VRTX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.